EUVIMEDEUVIMED entdecken
Leitlinie

Consensus guideline for the management of colorectal cancer with peritoneal metastases

Kurt S Schultz iD, Varun V Bansal iD, Michael M Wach, Neal Bhutiani iD, Frederick A Godley iD, Jaeyun Jane Wang iD, Muhammad Talha Waheed, Joanna T Buchheit iD, Emily Papai, Susan Campbell, Lauren E Schleimer, David G Su iD und 13 weitere

Cancer · 2025-07 · 131 (13)

DOI: 10.1002/cncr.35869 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Cancer, online erschienen am 25.06.2025. Verfasst von Kurt S Schultz und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Yale School of Medicine, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: Peritoneal Neoplasms, Colorectal Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 117 Literaturangaben. Gefördert von: Cancer Prevention and Research Institute of Texas, Irving Harris Foundation, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The peritoneum is a common site of metastases from colorectal cancer (CRC), yet controversy exists regarding optimal treatment strategies. These guidelines describe the results of a national consensus addressing the management of CRC with peritoneal metastases (CRC‐PM). An update of the 2018 Chicago consensus guidelines was conducted with a modified Delphi technique. Two rounds of voting were performed to assess agreement levels on two clinical management pathways regarding synchronous and metachronous CRC‐PM. Supporting evidence was evaluated via rapid literature reviews. The overall level of evidence was low in the existing literature. Of 145 participants in the first round, 136 (96.8%) responded in the second round. Over 90% consensus was achieved in most pathway blocks. For both pathways, early referral to a peritoneal surface malignancy center should be made for patients with CRC‐PM. For the synchronous pathway, upfront cytoreductive surgery was deemphasized in favor of systemic therapy. For the metachronous pathway, risk stratification via clinical and pathological features was revised. For both pathways, surveillance strategies were added, including only a weak recommendation for circulating tumor DNA testing, given limited evidence of its utility in detecting and monitoring PM. The consensus‐driven clinical pathways provide valuable guidance for the management of CRC‐PM. There remains a need for high‐quality evidence and prospective multicenter trials in this domain.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peritoneal NeoplasmsColorectal NeoplasmsHumansConsensusDelphi TechniqueCytoreduction Surgical ProceduresPractice Guidelines as Topic

Stichwörter der Autor:innen

circulating tumor DNA (ctDNA)colon cancercolorectal cancercytoreductive surgeryguidelinesintraperitoneal chemotherapyperitoneal surface malignanciesperitoneal surface neoplasmsrectal cancer

Autor:innen und Institutionen

  • Department of Surgery, Yale School of Medicine, New Haven, Connecticut, USA.
  • Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
  • Department of Colon and Rectal Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Surgery, University of Chicago Medical Center, Chicago, Illinois, USA.
  • Department of Surgery, University of California San Francisco, San Francisco, California, USA.
  • Department of Surgery, City of Hope National Medical Center, Duarte, California, USA.

ORCID-Profile: Kurt S Schultz, Varun V Bansal, Neal Bhutiani, Frederick A Godley, Jaeyun Jane Wang, Joanna T Buchheit, David G Su, Kiran K Turaga, Kanwal P S Raghav, Umut Sarpel, Ardaman P Shergill, Cathy Eng

Förderung

  • Cancer Prevention and Research Institute of Texas
  • Irving Harris Foundation
  • NCI NIH HHS
  • Conquer Cancer
  • NIH HHS

Zitieren

APA

Schultz, K. S., Bansal, V. V., Wach, M. M., Bhutiani, N., Godley, F. A., Wang, J. J., Waheed, M. T., Buchheit, J. T., Papai, E., Campbell, S., Schleimer, L. E., Su, D. G., Turaga, K. K., Gunderson, C. G., White, M. G., Uppal, A., Raghav, K. P. S., Labow, D. M., Sarpel, U., …, & Peritoneal Surface Malignancies Consortium Group (2025). Consensus guideline for the management of colorectal cancer with peritoneal metastases. Cancer, 131(13). https://doi.org/10.1002/cncr.35869

Vancouver

Schultz KS, Bansal VV, Wach MM, Bhutiani N, Godley FA, Wang JJ, et al. Consensus guideline for the management of colorectal cancer with peritoneal metastases. Cancer. 2025;131(13). doi:10.1002/cncr.35869

BibTeX
@article{Schultz2025,
  author = {Schultz, Kurt S and Bansal, Varun V and Wach, Michael M and Bhutiani, Neal and Godley, Frederick A and Wang, Jaeyun Jane and Waheed, Muhammad Talha and Buchheit, Joanna T and Papai, Emily and Campbell, Susan and Schleimer, Lauren E and Su, David G and Turaga, Kiran K and Gunderson, Craig G and White, Michael G and Uppal, Abhineet and Raghav, Kanwal P S and Labow, Daniel M and Sarpel, Umut and Shergill, Ardaman P and Shen, John Paul and Eng, Cathy and Foote, Michael B and Baumgartner, Joel M and Peritoneal Surface Malignancies Consortium Group, Peritoneal Surface Malignancies Consortium Group},
  title = {Consensus guideline for the management of colorectal cancer with peritoneal metastases},
  journal = {Cancer},
  year = {2025},
  volume = {131},
  number = {13},
  doi = {10.1002/cncr.35869}
}
Kostenlos starten →